Docetaxel and non-small cell lung cancer;Docetaxel et cancer bronchique non à petites cellules

Bulletin du Cancer

Volumn 91, Issue 3, 2004, Pages 263-270

  Le Guen, Yannick ^a   Le Cesne, Axel ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Docetaxel; Non small cell lung cancer; Radio chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REGIMEN; EVALUATION; HUMAN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; QUALITY OF LIFE; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CLINICAL TRIALS, PHASE III; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; TAXOIDS; VINBLASTINE;

EID: 2042513631     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Non-small cell lung cancer collaborative group. Chemotherapy in non-small lung cancer: a meta-analysis using updated data on individual patient from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
2. Fosella FV, Lee JS, Shin DM. Phase II study of docetaxel for advanced or metastatic platinium refractory non-small cell lung cancer. J Clin Oncol 1995; 13: 645-51.
3. Gandara DR, Vokes E, Green M, et al. Multicenter trial of docetaxel (taxotere) in platinium treated non-small cell lung cancer (NSCLC): confirmation of prolonged survival. Lung Cancer 1997; 18 (suppl. 1): 21.
4. 2 in platinium pretreated advanced non small lung cancer (NSCLC). Proc Am Soc Clin Oncol 1999; 18: 18a.
5. Alexopoulos K, Kouroussis C, Androulakis N, et al. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial. Cancer Chemother Pharmacol 1999; 43: 257-62.
6. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non small cell lung cancer previously treated with platinium-based chemotherapy. J Clin Oncol 2000; 18: 2095-103.
7. Fosella FV, De Vore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine in patients with advanced small cell lung cancer previously treated with platinium containing chemotherapy regimens. J Clin Oncol 2000; 18: 2354-62.
8. Rigas JR. Single agent docetaxel in previously untreated non-small cell lung cancer. Oncology 1997; 11 (suppl. 7): 17-21.
9. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995; 75: 968-72.
10. Kunitoh H, Watanabe K, Onoshi T, et al. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer : a Japanese cooperative study. J Clin Oncol 1996; 14: 1649-55.
11. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 37: 145-57.
12. Hainsworth JD, Burris HA 3rd, Litchy S, et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma: a Minnie Pearl Cancer Research Network Phase II Trial. Cancer 2000; 89: 328-33.
13. 2 weekly in patients with pretreayed non small lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21: 310a.
14. Schütte W, Nagel S, Lautenschläger C, et al. Randomized phase III study of weekly versus three weekly docetaxel as second line chemotherapy for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21: 308a.
15. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a european multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-7.
16. Khuri FR. Docetaxel for locally advanced or metastatic non-small cell lung cancer: current data and future directions as front-line therapy. Oncology 2002; 16 (suppl. 6): 53-62.
17. Kim YH, Kim JS, Choi YH, et al. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer. Int J Clin Oncol 2002; 7: 114-9.
18. Zalcberg J, Millward M, Bishop J, et al. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 1998; 16: 1948-53.
19. Le Chevalier T, Monnier A, Douillard JY, et al. Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer 1998; 34: 2032-6.
20. Georgoulias V, Androulakis N, Dimopoulos AM, et al. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II srudy. Ann Oncology 1998; 9: 331-4.
21. Cole JT, Gralla RJ, Rittenberg CN, et al. Defining the dose of docetaxel (taxotere) in combination chemotherapy of non small cell lung cancer: preserving efficacy with lower dose regimens. Proc Am Soc Clin Oncol 1997; 16: 465b.
22. Faderl B, von Pawel J, Wagner H, et al. Phase II study of docetaxel and cisplatin in a circadian timing as first line chemotherapy (CT) in advanced non small cell lung cancer (NSCLC). Eur J Cancer 1999; 35: 256.
23. Niho S, Ohe Y, Kakinuma R, et al. Phase II study of docetaxel and cisplatin administred as three consecutive weekly infusions for advanced non-small cell lung cancer. Lung Cancer 2002; 35: 209-14.
24. Ramalingam S, Bonomi T, Dobbs T, et al. Docetaxel and carboplatin for advanced non small cell lung cancer (NSCLC): dose of carboplatin, influences outcome. Proc Am Soc Clin Oncol 2002; 21: 316a.
25. Belani CP, Einzig A, Bonomi P, et al. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol 2000; 11: 673-8.
26. Harvey J, Windsor K, Lasker J, et al. A phase II study of docetaxel and carboplatin with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000; 19: 511a.
27. Jahanzeb M, Sarna G, Hirsch R, et al. A multicenter phase II trial of carboplatin and docetaxel in previously untreated advanced non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 2000; 19: 514a.
28. Arcenas AG, Karkera D, Krasnow S, et al. A phase II trial of carboplatin and docetaxel for stage IIIB/IV non-small cell lung cancer. Proc Am Soc Clin Oncol 2001; 20: 274b.
29. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-98.
30. Fossella F. Docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCc) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer (NSCLC): results of a multicenter, randomized phase III study. Eur J Cancer 2001; 37: S154.
31. Coudert B, Rivière A, Douillard J, et al. Final results of a phase II randomized study of taxotere + cisplatin versus vinorelbine + cisplatin in patients with stage IV non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21: abstract 1296.
32. Kubota K, Watanabe K, Kunitoh H, et al. Final results of a randomized phase III trial of docetaxel and cisplatin in stage IV non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21: abstract 1180.
33. McKay C, Hainsworth J, Burris H, et al. Weekly docetaxel/gemcitabine in the treatment of eldery patients (pts) with advanced non-small cell lung cancer (NSCLC): a Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 2001; 21: 260b.
34. Neubauer M, Garfield D, Khan M, et al. Phase II trial of weekly docetaxel (Taxotere) plus gemcitabine (Gemzar) as first line therapy for patients (pts) with advanced non-small cell lung cancer (ANSCLC). Proc Am Soc Clin Oncol 2001; 20: 252b.
35. Popa IE, Stewart K, Smith FP, et al. A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced non-small cell lung carcinoma. Cancer 2002; 95: 1714-9.
36. Galetta D, Gebbia V, Giotta F, et al. Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2002; 38: 79-84.
37. Georgoulias V, Kouroussis C, Androulakis N, et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol 1999; 17: 914-20.
38. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001; 357: 1478-84.
39. Kakolyris S, Tsiafaki X, Agelidou A, et al. Preliminary results of a multicenter randomized phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2002; 21: 296a.
40. Miller VA, Krug LM, Ng KK, et al. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18: 1346-50.
41. Kourousis C, Androulakis N, Kakolyris S, et al. First-line treatment of advanced non-small cell lung carcinoma with docetaxel and vinorelbine. Cancer 1998; 83: 2083-90.
42. Bennouna J, Monnier A, Rivi A, Milleron B, et al. A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer. Eur J Cancer 2000; 36: 1107-12.
43. Papadimitrakopoulou V, Lozada JA, Henderson T, et al. A phase II study of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer as front-line and second line therapy. Proc Am Soc Clin Oncol 2001; 20: 259b.
44. Pectasides D, Aspropotamitis A, Halikia A, et al. Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1999; 17: 3816-21.
45. Tezcan H, Grosset AB, Tezcan AZ, et al. Weekly chemotherapy with docetaxel, carboplatin and gemcitabine in stage IIIB, and IV non-small cell lung cancer: a phase II study. Proc Am Soc Clin Oncol 2002; 21: 235b.
46. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 673-80.
47. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330: 153-8.
48. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stageI (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20: 247-53.
49. Rosell R. New approaches in the adjuvant and neoadjuvant therapy of non-small cell lung cancer, including docetaxel (Taxotere) combinations. Semin Oncol 1999; 26 (suppl. 11): 32-7.
50. Betticher DC, Hsu Schmitz SF, Hansen E, et al. Neoadjuvant therapy with docetaxel (TAX) and cisplatin (CIS) in patients (pts) with non small cell lung cancer (NSCLC), stage IIIA, pN2 is active with a promising survival rate. Proc Am Soc Clin Oncol 2002; 21: 308a.
51. Dediu M, Horvat T, Tarlea A, et al. Docetaxel plus cisplatin as neoadjuvant chemotherapy for unresectable stage III non-small-cell lung cancer (NSCLC): a comparison of two schedules. Proc Am Soc Clin Oncol 2002; 21: 235b.
52. Dillman RO, Herndon J, Seagren S, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210-5.
53. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83: 417-23.
54. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-9.
55. Mornex F, Robinet G, Thomas P, et al. Sequential versus concurrent chemoradiation in locally advanced non-small cell lung cancer : a french randomized phase III trial of GLOT-GFPC (NPC 95-01 study). Eur J Cancer 2001; 37 (suppl. 6): S28.
56. Curran W, Scott C, Langer C, et al. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): initial report of radiation therapy oncology group (RTOG 9410). Proc Am Soc Clin Oncol 2000; 19: 484.
57. Kim ES, Khuri FR. Docetaxel and radiation as combined-modality therapy. Oncology 2002; 16 (suppl. 6): 97-105.
58. Gaspar L, Gandara D, Chansky K, et al. Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIb non-small-cell lung cancer (NSCLC): patterns of failure and updated survival. Proc Am Soc Clin Oncol 2001; 20: abstract 1255.